Qualified institutional buyers were at the forefront of bidding and subscribed 92.94 times their allotted quota. On the other hand Non-Institutional investors took 42.57 times.The employees of the drugmaker placed bids of 7.9 times which were allotted to them and the retail investors took 6.33 times.Kotak Mahindra Capital Company Ltd, Axis Capital Ltd, J.P Morgan India Private Ltd, and Jefferies India Private ltd were the lead book running managers of the IPO.Emcure Pharmaceuticals founded in 1981 by Satish Mehta has come a long way. Initially it started out as manufacturing drugs for multinational pharma on contractual basis. Mehta finished his PG diploma from IIM-A and his passion drove him to the path of entrepreneurial journey of starting his drug manufacturing venture.The company today has expanded across India and it has 13 manufacturing units. It globally market a variety of dosage. The drugmaker does research and develops its own dosage with a product ranging from orals, injectables and biotherapeutics. The company has a market base in around 70 countries.
sekar nallalu Cryptocurrency,Markets Emcure Pharma, 43-Years Old Drugmaker Enters Dalal Street with 31% Premium
Related Posts
Rare twin panda birth: a historic milestone in endangered species conservation
The world of zoology received wonderful news recently, as a pair of giant panda twins were born in a Hong[...]
Unraveling the gamestop slide: a comprehensive analysis and its impact on investment strategies
GameStop shares have become a talking point in finance circles and among casual investors alike ever since their meteoric rise[...]
Analyzing bitcoin’s recent drop below $50k: the interplay of short and long-term holders
Welcome once again to another insightful piece on the dynamic world of cryptocurrencies. Today, we’ll dissect the driving factors that[...]